SCHEMBL8935044

SCHEMBL8935044

O=c1[nH]ccc2cc(OC3CCN(Cc4cccc5ccccc45)CC3)c(Cl)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 2/20 0.57
ACHE P22303 1/20 0.45
OPRM1 P35372 3/20 0.44
OPRK1 P41145 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
OPRL1 P41146 2/20 0.43
ROCK1 Q13464 1/20 0.41
DRD4 P21917 2/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
GPR84 Q9NQS5 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SCN1A P35498 1/20 0.39
SCN8A Q9UQD0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937942 0.89 ROCK1 (0.55) MAP2K1ACHEOPRM1OPRK1MEN1
SCHEMBL8934981 0.87 MAP2K1 (0.59) MAP2K1ROCK1SCN1ASCN8A
SCHEMBL8935042 0.85 MAP2K1 (0.54) MAP2K1ACHEOPRM1MEN1KMT2A
SCHEMBL8934976 0.85 MAP2K1 (0.56) MAP2K1OPRM1MEN1KMT2AROCK1
SCHEMBL8938119 0.84 MAP2K1 (0.55) MAP2K1ACHEOPRM1SIGMAR1SCN1A
SCHEMBL8934886 0.83 ROCK1 (0.56) ACHEOPRM1OPRK1OPRL1ROCK1
SCHEMBL8938278 0.83 MAP2K1 (0.59) MAP2K1OPRM1ROCK1SCN1ASCN8A
SCHEMBL8937951 0.83 ROCK1 (0.52) MAP2K1ACHEOPRM1MEN1KMT2A
SCHEMBL8938694 0.83 MAP2K1 (0.54) MAP2K1OPRM1OPRK1MEN1KMT2A
SCHEMBL8934996 0.82 MAP2K1 (0.58) MAP2K1ROCK1SCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 MAP2K1 1916/4885ACHE 3559/4885OPRM1 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.